Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma

Kohei Kobatake, Keisuke Goto, Yohei Sekino, Kazuma Yukihiro, Miki Naito, Kenshiro Takemoto, Shunsuke Miyamoto, Hiroyuki Kitano, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata

Open source

DOI
10.1038/s41598-026-59145-y
Published
2026-06-30
Container
Scientific Reports
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41598-026-59145-y,
  title = {Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma},
  author = {Kohei Kobatake and Keisuke Goto and Yohei Sekino and Kazuma Yukihiro and Miki Naito and Kenshiro Takemoto and Shunsuke Miyamoto and Hiroyuki Kitano and Akihiro Goriki and Keisuke Hieda and Nobuyuki Hinata},
  year = {2026},
  journal = {Scientific Reports},
  doi = {10.1038/s41598-026-59145-y},
  url = {https://doi.org/10.1038/s41598-026-59145-y}
}

RIS

TY  - JOUR
TI  - Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma
AU  - Kohei Kobatake
AU  - Keisuke Goto
AU  - Yohei Sekino
AU  - Kazuma Yukihiro
AU  - Miki Naito
AU  - Kenshiro Takemoto
AU  - Shunsuke Miyamoto
AU  - Hiroyuki Kitano
AU  - Akihiro Goriki
AU  - Keisuke Hieda
AU  - Nobuyuki Hinata
PY  - 2026
JO  - Scientific Reports
DO  - 10.1038/s41598-026-59145-y
UR  - https://doi.org/10.1038/s41598-026-59145-y
ER  - 

APA

Kobatake, K., Goto, K., Sekino, Y., Yukihiro, K., Naito, M., Takemoto, K., Miyamoto, S., Kitano, H., Goriki, A., Hieda, K., & Hinata, N. (2026). Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma. Scientific Reports. https://doi.org/10.1038/s41598-026-59145-y

Source records